Metagenomi Therapeutics, Inc. SEC filings MGX
Metagenomi Therapeutics, Inc. has 154 filings in SEC EDGAR's recent list, going back to Aug 16, 2019. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Sep 11, 2026 | Sep 9, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 10, 2026 | — |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Mar 5, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Mar 5, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 144 | Notice of proposed sale | Sep 11, 2025 | — |
| 4 | Insider transaction | Sep 2, 2025 | Sep 2, 2025 |
| 3 | Initial insider ownership | Aug 15, 2025 | Aug 11, 2025 |
| 144 | Notice of proposed sale | Jul 9, 2025 | — |
| 4 | Insider transaction | Jun 12, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 12, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 12, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Mar 7, 2025 | Mar 5, 2025 |
| 4 | Insider transaction | Mar 7, 2025 | Mar 5, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 3 | Initial insider ownership | Jan 27, 2025 | Jan 27, 2025 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 5, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 6, 2024 | — |
| 4 | Insider transaction | Sep 6, 2024 | Sep 5, 2024 |
| SC 13G | Ownership over 5% (passive) | May 10, 2024 | — |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Feb 15, 2024 | Feb 9, 2024 |
| 4 | Insider transaction | Feb 15, 2024 | Feb 13, 2024 |
| 3 | Initial insider ownership | Feb 15, 2024 | Feb 8, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 13, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
Showing 78 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MGX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1785279
- Former names
- Metagenomi, Inc. (until Jan 12, 2026); Metagenomi Technologies, LLC (until Jan 18, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.